Status:
SUSPENDED
Assess the Absorption, Distribution, Metabolism and Excretion of AZD7325 After Intravenous and Oral Administration
Lead Sponsor:
AstraZeneca
Conditions:
Absorption
Distribution
Eligibility:
MALE
35-50 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the absorption, distribution, metabolism and excretion of AZD7325 after intravenous and 14C labeled oral dose
Eligibility Criteria
Inclusion
- Healthy subjects Day 1
- Body Mass Index (BMI) \> 18 and \< 30kg/m2
Exclusion
- Clinically relevant disease and abnormalities (past or present) which in the opinion of the investigator, may either put the subject at risk to participate in this study or may influence the results of the study or the subject's ability to participate in the study
- Use of prescription medication within 14 days of the first dose of the investigational product
- Blood loss in excess of 200 mL within 30 days of Day-1 in excess of 500 mL within 90 days of Day-1 or in excess of 1350 mL within 1 year of Day-1 or donation of blood products within 14 days of Day -1
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2009
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00940641
Start Date
August 1 2009
End Date
October 1 2009
Last Update
January 24 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Alderley Park, United Kingdom